OrthoPediatrics (NASDAQ:KIDS) Now Covered by Lake Street Capital

Research analysts at Lake Street Capital started coverage on shares of OrthoPediatrics (NASDAQ:KIDS - Get Free Report) in a research note issued on Monday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $37.00 price target on the stock. Lake Street Capital's target price suggests a potential upside of 74.86% from the stock's previous close.

A number of other analysts have also recently weighed in on the company. Truist Financial decreased their price objective on OrthoPediatrics from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Stifel Nicolaus dropped their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, OrthoPediatrics presently has an average rating of "Moderate Buy" and an average price target of $37.00.

OrthoPediatrics Stock Performance

Shares of OrthoPediatrics stock traded down $0.23 during trading on Monday, reaching $21.16. The company's stock had a trading volume of 142,007 shares, compared to its average volume of 200,282. The company has a 50-day moving average price of $24.20 and a two-hundred day moving average price of $24.76. OrthoPediatrics has a fifty-two week low of $20.78 and a fifty-two week high of $35.99. The firm has a market cap of $513.91 million, a PE ratio of -17.20 and a beta of 1.17. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same period in the previous year, the business posted ($0.23) earnings per share. On average, analysts forecast that OrthoPediatrics will post -0.93 EPS for the current year.

Insider Activity at OrthoPediatrics

In related news, CEO David R. Bailey sold 6,620 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. The trade was a 2.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. The trade was a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock worth $589,978 over the last 90 days. Company insiders own 31.80% of the company's stock.

Institutional Trading of OrthoPediatrics

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP acquired a new position in shares of OrthoPediatrics during the 3rd quarter worth approximately $25,000. R Squared Ltd acquired a new position in shares of OrthoPediatrics in the fourth quarter worth $48,000. KLP Kapitalforvaltning AS acquired a new position in shares of OrthoPediatrics in the fourth quarter worth $79,000. BNP Paribas Financial Markets lifted its position in shares of OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock valued at $94,000 after acquiring an additional 1,929 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of OrthoPediatrics during the fourth quarter valued at $171,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.